MedTrace Logo

A Study of BBP-711 (ORF-229) in Healthy Adult Volunteers

NCT04876924 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2022-03-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of BBP-711 in healthy adult volunteers.

Conditions

  • Healthy

Interventions

DRUG

BBP-711

BBP-711, oral suspension

DRUG

Placebo

Placebo matching BBP-711

Sponsors & Collaborators

  • Celerion

    collaborator INDUSTRY

  • Cantero Therapeutics, a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Terry O'Reilly, MD · Celerion

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2022-02-27
Completion
2022-02-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04876924 on ClinicalTrials.gov